17764-92-0Relevant articles and documents
The synthesis of a selective PDE4/TNFα inhibitor
Caron, Stephane,Vazquez, Enrique
, p. 587 - 592 (2001)
Two syntheses of cis-4-cyano-4-(1-cyclohexyl-3-ethyl-1H-indazol-6-yl)cyclohexanecarboxylic acid (1), a selective PDE4/TNFα inhibitor are described. The first synthesis relied on a solvolysis of a tertiary benzylic alcohol to the nitrile using T
HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK
-
Paragraph 0175, (2014/05/24)
Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.
ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS
-
Page/Page column 109, (2009/10/22)
The present invention provides a compound of formula (I):said compound is inhibitor of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP- 13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12, and/or MMP- 13. Finally, the present invention also provides a pharmaceutical composition.